Bronchodilators Market by Drug class (Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor and Combination Drugs), by Indication (Asthma, COPD, and Others), and Route of Administration (Oral, Injection, and Inhaler): Global Opportunity Analysis and Industry Forecast, 2019–2026
The global bronchodilators market was valued at $27,580.00 million in 2018 and is expected to reach $41,487.53 million by 2026, registering a CAGR of 5.2% from 2019 to 2026. Bronchodilators are drugs that relax muscles that tighten around the airways. These drugs open airways and allow more air to move in and out of lungs. They are also used to reduce mucus from lungs. Patients suffering from respiratory disorders consume these drugs through the help of nebulizers or inhalers. In addition, inhaler bronchodilators have effects on mucociliary clearance as well. Bronchodilators are used in the treatment of obstructive lung diseases by relaxing the lung muscles and widening the airways (bronchi). They are used in the treatment of asthma and chronic obstructive pulmonary diseases (COPD).
Surge in prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD) across the globe is the major factor driving the bronchodilators market growth. Other factors such as rise in incidence of respiratory diseases due to cigarette smoking also boost the market growth. In addition, rise in disposable income, geriatric population, and increase in awareness for healthcare among people are anticipated to boost the market growth. However, side effects associated with bronchodilators and government regulations related to the safety & efficacy of these drugs are anticipated to hamper the market growth. Furthermore, ongoing R&D activities related to bronchodilators are anticipated to present new opportunities for the market.
The market is segmented on the basis of indication, drug type, route of administration, and region. On the basis of indication, it is categorized into asthma, chronic obstructive pulmonary disease (COPD), and others. By drug type, it is classified into sympathomimetics, anticholinergics, phosphodiesterase inhibitors, and combination drugs. On the basis of route of administration, it is categorized into oral, injection, and inhaler. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vectura Group plc., and Abbott Laboratories are provided in this report.
KEY BENEFITS FOR STAKEHOLDERS
By Indication
Surge in prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD) across the globe is the major factor driving the bronchodilators market growth. Other factors such as rise in incidence of respiratory diseases due to cigarette smoking also boost the market growth. In addition, rise in disposable income, geriatric population, and increase in awareness for healthcare among people are anticipated to boost the market growth. However, side effects associated with bronchodilators and government regulations related to the safety & efficacy of these drugs are anticipated to hamper the market growth. Furthermore, ongoing R&D activities related to bronchodilators are anticipated to present new opportunities for the market.
The market is segmented on the basis of indication, drug type, route of administration, and region. On the basis of indication, it is categorized into asthma, chronic obstructive pulmonary disease (COPD), and others. By drug type, it is classified into sympathomimetics, anticholinergics, phosphodiesterase inhibitors, and combination drugs. On the basis of route of administration, it is categorized into oral, injection, and inhaler. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vectura Group plc., and Abbott Laboratories are provided in this report.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
By Indication
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Others
- Sympathomimetics
- Anticholinergics
- Phosphodiesterase Inhibitor
- Combination Drugs
- Oral
- Injection
- Inhaler
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Boehringer Ingelheim
- GlaxoSmithKline
- F. Hoffmann-La Roche AG
- AstraZeneca plc
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd
- Vectura Group plc.
- Abbott Laboratories
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of buyers
3.3.2. Low bargaining power of suppliers
3.3.3. Moderate threat of substitutes
3.3.4. Low threat of new entrants
3.3.5. Moderate competitive rivalry
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in incidence of asthma and COPD
3.5.1.2. Surge in government initiatives
3.5.2. Restraint
3.5.2.1. Side effects associated with bronchodilators
3.5.3. Opportunity
3.5.3.1. Various growth opportunities in emerging economies
CHAPTER 4: BRONCHODILATORS MARKET, BY INDICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Asthma
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market share analysis, by country
4.3. Chronic obstructive pulmonary disease (COPD)
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.3.3. Market share analysis, by country
4.4. Others
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market share analysis, by country
CHAPTER 5: BRONCHODILATORS MARKET, BY DRUG TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Sympathomimetics
5.2.1. Market size and forecast
5.2.2. Market share analysis, by country
5.3. Anticholinergics
5.3.1. Market size and forecast
5.3.2. Market share analysis, by country
5.4. Phosphodiesterase Inhibitors
5.4.1. Market size and forecast
5.4.2. Market share analysis, by country
5.5. Combination Drugs
5.5.1. Market size and forecast
5.5.2. Market share analysis, by country
CHAPTER 6: BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Oral
6.2.1. Market size and forecast
6.2.2. Market share analysis, by country
6.3. Injection
6.3.1. Market size and forecast
6.3.2. Market share analysis, by country
6.4. Inhalers
6.4.1. Market size and forecast
6.4.2. Market share analysis, by country
CHAPTER 7: BRONCHODILATORS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by indication
7.2.4. Market size and forecast, by drug type
7.2.5. Market size and forecast, by route of administration
7.2.5.1. U.S. market size and forecast, by indication
7.2.5.2. U.S. market size and forecast, by drug type
7.2.5.3. U.S. market size and forecast, by route of administration
7.2.5.4. Canada market size and forecast, by indication
7.2.5.5. Canada market size and forecast, by drug type
7.2.5.6. Canada market size and forecast, by route of administration
7.2.5.7. Mexico market size and forecast, by indication
7.2.5.8. Mexico market size and forecast, by drug type
7.2.5.9. Mexico market size and forecast, by route of administration
7.3. Europe
7.3.1. Key growth factors and opportunities
7.3.2. Europe Market size and forecast, by country
7.3.3. Europe Market size and forecast, by indication
7.3.4. Europe Market size and forecast, by drug type
7.3.5. Europe Market size and forecast, by route of administration
7.3.5.1. Germany market size and forecast, by indication
7.3.5.2. Germany market size and forecast, by drug type
7.3.5.3. Germany market size and forecast, by route of administration
7.3.5.4. France market size and forecast, by indication
7.3.5.5. France market size and forecast, by drug type
7.3.5.6. France market size and forecast, by route of administration
7.3.5.7. UK market size and forecast, by indication
7.3.5.8. UK market size and forecast, by drug type
7.3.5.9. UK market size and forecast, by route of administration
7.3.5.10. Rest of Europe market size and forecast, by indication
7.3.5.11. Rest of Europe market size and forecast, by drug type
7.3.5.12. Rest of Europe market size and forecast, by route of administration
7.4. Asia-Pacific
7.4.1. Key growth factors and opportunities.
7.4.2. Asia-Pacific market size and forecast, by country
7.4.3. Asia-Pacific market size and forecast, by indication
7.4.4. Asia-Pacific market size and forecast, by drug type
7.4.5. Asia-Pacific market size and forecast, by route of administration
7.4.6.1. Japan market size and forecast, by indication
7.4.6.2. Japan market size and forecast, by drug type
7.4.6.3. Japan market size and forecast, by route of administration
7.4.6.4. China market size and forecast, by indication
7.4.6.5. China market size and forecast, by drug type
7.4.6.6. China market size and forecast, by route of administration
7.4.6.7. India market size and forecast, by indication
7.4.6.8. India market size and forecast, by drug type
7.4.6.9. India market size and forecast, by route of administration
7.4.6.11. Rest of Asia-Pacific market size and forecast by indication
7.4.6.12. Rest of Asia-Pacific market size and forecast, by drug type
7.4.6.13. Rest of Asia-Pacific market size and forecast, by route of administration
7.5. LAMEA
7.5.1. Key growth factors and opportunities
7.5.2. Market size and forecast, by country
7.5.3. LAMEA market size and forecast, by indication
7.5.4. LAMEA market size and forecast, by drug type
7.5.5. LAMEA market size and forecast, by route of administration
7.5.5.1. Brazil market size and forecast, by indication
7.5.5.2. Brazil market size and forecast, by drug type
7.5.5.3. Brazil market size and forecast, by route of administration
7.5.5.4. Saudi Arabia market size and forecast, by indication
7.5.5.5. Saudi Arabia market size and forecast, by drug type
7.5.5.6. Saudi Arabia market size and forecast, by route of administration
7.5.5.7. South Africa market size and forecast, by indication
7.5.5.8. South Africa market size and forecast, by drug type
7.5.5.9. South Africa market size and forecast, by route of administration
7.5.5.10. Rest of LAMEA market size and forecast, by indication
7.5.5.11. Rest of LAMEA market size and forecast, by drug type
7.5.5.12. Rest of LAMEA market size and forecast, by route of administration
CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. AstraZeneca plc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Boehringer Ingelheim International GmbH
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. GlaxoSmithKline Plc.
8.4.1. Company overview
8.4.2. Operating business segments
8.4.3. Product portfolio
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. F. Hoffmann-La Roche Ltd.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. Novartis AG.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Pfizer Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. SANOFI
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Teva Pharmaceutical Industries Ltd.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Vectura Group Plc.
8.10.1. Company overview
8.10.2. Operating business segments
8.10.3. Product portfolio
8.10.4. Business performance
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of buyers
3.3.2. Low bargaining power of suppliers
3.3.3. Moderate threat of substitutes
3.3.4. Low threat of new entrants
3.3.5. Moderate competitive rivalry
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in incidence of asthma and COPD
3.5.1.2. Surge in government initiatives
3.5.2. Restraint
3.5.2.1. Side effects associated with bronchodilators
3.5.3. Opportunity
3.5.3.1. Various growth opportunities in emerging economies
CHAPTER 4: BRONCHODILATORS MARKET, BY INDICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Asthma
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market share analysis, by country
4.3. Chronic obstructive pulmonary disease (COPD)
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.3.3. Market share analysis, by country
4.4. Others
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market share analysis, by country
CHAPTER 5: BRONCHODILATORS MARKET, BY DRUG TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Sympathomimetics
5.2.1. Market size and forecast
5.2.2. Market share analysis, by country
5.3. Anticholinergics
5.3.1. Market size and forecast
5.3.2. Market share analysis, by country
5.4. Phosphodiesterase Inhibitors
5.4.1. Market size and forecast
5.4.2. Market share analysis, by country
5.5. Combination Drugs
5.5.1. Market size and forecast
5.5.2. Market share analysis, by country
CHAPTER 6: BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Oral
6.2.1. Market size and forecast
6.2.2. Market share analysis, by country
6.3. Injection
6.3.1. Market size and forecast
6.3.2. Market share analysis, by country
6.4. Inhalers
6.4.1. Market size and forecast
6.4.2. Market share analysis, by country
CHAPTER 7: BRONCHODILATORS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by indication
7.2.4. Market size and forecast, by drug type
7.2.5. Market size and forecast, by route of administration
7.2.5.1. U.S. market size and forecast, by indication
7.2.5.2. U.S. market size and forecast, by drug type
7.2.5.3. U.S. market size and forecast, by route of administration
7.2.5.4. Canada market size and forecast, by indication
7.2.5.5. Canada market size and forecast, by drug type
7.2.5.6. Canada market size and forecast, by route of administration
7.2.5.7. Mexico market size and forecast, by indication
7.2.5.8. Mexico market size and forecast, by drug type
7.2.5.9. Mexico market size and forecast, by route of administration
7.3. Europe
7.3.1. Key growth factors and opportunities
7.3.2. Europe Market size and forecast, by country
7.3.3. Europe Market size and forecast, by indication
7.3.4. Europe Market size and forecast, by drug type
7.3.5. Europe Market size and forecast, by route of administration
7.3.5.1. Germany market size and forecast, by indication
7.3.5.2. Germany market size and forecast, by drug type
7.3.5.3. Germany market size and forecast, by route of administration
7.3.5.4. France market size and forecast, by indication
7.3.5.5. France market size and forecast, by drug type
7.3.5.6. France market size and forecast, by route of administration
7.3.5.7. UK market size and forecast, by indication
7.3.5.8. UK market size and forecast, by drug type
7.3.5.9. UK market size and forecast, by route of administration
7.3.5.10. Rest of Europe market size and forecast, by indication
7.3.5.11. Rest of Europe market size and forecast, by drug type
7.3.5.12. Rest of Europe market size and forecast, by route of administration
7.4. Asia-Pacific
7.4.1. Key growth factors and opportunities.
7.4.2. Asia-Pacific market size and forecast, by country
7.4.3. Asia-Pacific market size and forecast, by indication
7.4.4. Asia-Pacific market size and forecast, by drug type
7.4.5. Asia-Pacific market size and forecast, by route of administration
7.4.6.1. Japan market size and forecast, by indication
7.4.6.2. Japan market size and forecast, by drug type
7.4.6.3. Japan market size and forecast, by route of administration
7.4.6.4. China market size and forecast, by indication
7.4.6.5. China market size and forecast, by drug type
7.4.6.6. China market size and forecast, by route of administration
7.4.6.7. India market size and forecast, by indication
7.4.6.8. India market size and forecast, by drug type
7.4.6.9. India market size and forecast, by route of administration
7.4.6.11. Rest of Asia-Pacific market size and forecast by indication
7.4.6.12. Rest of Asia-Pacific market size and forecast, by drug type
7.4.6.13. Rest of Asia-Pacific market size and forecast, by route of administration
7.5. LAMEA
7.5.1. Key growth factors and opportunities
7.5.2. Market size and forecast, by country
7.5.3. LAMEA market size and forecast, by indication
7.5.4. LAMEA market size and forecast, by drug type
7.5.5. LAMEA market size and forecast, by route of administration
7.5.5.1. Brazil market size and forecast, by indication
7.5.5.2. Brazil market size and forecast, by drug type
7.5.5.3. Brazil market size and forecast, by route of administration
7.5.5.4. Saudi Arabia market size and forecast, by indication
7.5.5.5. Saudi Arabia market size and forecast, by drug type
7.5.5.6. Saudi Arabia market size and forecast, by route of administration
7.5.5.7. South Africa market size and forecast, by indication
7.5.5.8. South Africa market size and forecast, by drug type
7.5.5.9. South Africa market size and forecast, by route of administration
7.5.5.10. Rest of LAMEA market size and forecast, by indication
7.5.5.11. Rest of LAMEA market size and forecast, by drug type
7.5.5.12. Rest of LAMEA market size and forecast, by route of administration
CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. AstraZeneca plc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Boehringer Ingelheim International GmbH
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. GlaxoSmithKline Plc.
8.4.1. Company overview
8.4.2. Operating business segments
8.4.3. Product portfolio
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. F. Hoffmann-La Roche Ltd.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. Novartis AG.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Pfizer Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. SANOFI
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Teva Pharmaceutical Industries Ltd.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Vectura Group Plc.
8.10.1. Company overview
8.10.2. Operating business segments
8.10.3. Product portfolio
8.10.4. Business performance
LIST OF TABLES
TABLE 01. BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 02. BRONCHODILATORS MARKET FOR ASTHMA MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. BRONCHODILATORS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018–2026 ($MILLION)
TABLE 04. BRONCHODILATORS MARKET FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 05. BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 06. SYMPATHOMIMETICS BRONCHODILATORS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. BRONCHODILATORS FOR ANTICHOLINERGICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. BRONCHODILATORS MARKET FOR PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018–2026 ($MILLION)
TABLE 09. BRONCHODILATORS MARKET FOR COMBINATION DRUGS, BY REGION, 2018–2026 ($MILLION)
TABLE 10. BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 11. BRONCHODILATORS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2018–2026 ($MILLION)
TABLE 12. BRONCHODILATORS MARKET FOR INJECTION, BY REGION, 2018–2026 ($MILLION)
TABLE 13. BRONCHODILATORS MARKET FOR INHALE, BY REGION, 2018–2026 ($MILLION)
TABLE 14. BRONCHODILATORS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 15. NORTH AMERICA BRONCHODILATORS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 16. NORTH AMERICA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 17. NORTH AMERICA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 18. NORTH AMERICA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 19. U.S. BRONCHODILATORS MARKET BY INDICATION, 2018–2026 ($MILLION)
TABLE 20. U.S. BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 21. U.S. BRONCHODILATORS MARKET BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 22. CANADA BRONCHODILATORS MARKET BY INDICATION, 2018–2026 ($MILLION)
TABLE 23. CANADA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 24. CANADA BRONCHODILATORS MARKET BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 25. MEXICO BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 26. MEXICO BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 27. MEXICO BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 28. EUROPE BRONCHODILATORS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 29. EUROPE BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 30. EUROPE BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION),
TABLE 31. EUROPE BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 32. GERMANY BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 33. GERMANY BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 34. GERMANY BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 35. FRANCE BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 36. FRANCE BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 37. FRANCE BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 38. U.K. BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 39. U.K. BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 40. U.K. BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 41. REST OF EUROPE BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 42. REST OF EUROPE BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 43. REST OF EUROPE BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 44. ASIA-PACIFIC BRONCHODILATORS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 45. ASIA-PACIFIC BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 46. ASIA-PACIFIC BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION),
TABLE 47. ASIA-PACIFIC BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 48. JAPAN BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 49. JAPAN BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 50. JAPAN BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 51. CHINA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 52. CHINA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 53. CHINA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 54. INDIA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 55. INDIA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 56. INDIA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 57. REST OF ASIA-PACIFIC BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 58. REST OF ASIA-PACIFIC BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 59. REST OF ASIA-PACIFIC BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 60. LAMEA BRONCHODILATORS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 61. LAMEA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 62. LAMEA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION),
TABLE 63. LAMEA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 64. BRAZIL BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 65. BRAZIL BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 66. BRAZIL BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 67. SAUDI ARABIA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 68. SAUDI ARABIA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 69. SAUDI ARABIA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 70. SOUTH AFRICA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 71. SOUTH AFRICA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 72. SOUTH AFRICA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 73. REST OF LAMEA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 74. REST OF LAMEA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 75. REST OF LAMEA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 76. ABBOTT: COMPANY SNAPSHOT
TABLE 77. ABBOTT: OPERATING BUSINESS SEGMENTS
TABLE 78. ABBOTT PRODUCT PORTFOLIO
TABLE 79. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 80. ASTRAZENECA: OPERATING BUSINESS SEGMENTS
TABLE 81. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 82. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 83. BOEHRINGER INGELHEIM: PRODUCT BUSINESS SEGMENTS
TABLE 84. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 85. GSK.: COMPANY SNAPSHOT
TABLE 86. GSK.: OPERATING BUSINESS SEGMENTS
TABLE 87. GSK.: PRODUCT PORTFOLIO
TABLE 88. ROCHE: COMPANY SNAPSHOT
TABLE 89. ROCHE: OPERATING SEGMENTS
TABLE 90. NOVARTIS: COMPANY SNAPSHOT
TABLE 91. NOVARTIS: OPERATING BUSINESS SEGMENTS
TABLE 92. NOVARTIS: PRODUCT PORTFOLIO
TABLE 93. PFIZER: COMPANY SNAPSHOT
TABLE 94. PFIZER: OPERATING SEGMENTS
TABLE 95. PFIZER: PRODUCT PORTFOLIO
TABLE 96. SANOFI: COMPANY SNAPSHOT
TABLE 97. SANOFI: OPERATING SEGMENTS
TABLE 98. SANOFI: PRODUCT PORTFOLIO
TABLE 99. TEVA: COMPANY SNAPSHOT
TABLE 100. TEVA: PRODUCT PORTFOLIO
TABLE 101. VECTURA: COMPANY SNAPSHOT
TABLE 102. VECTURA: PRODUCT PORTFOLIO
TABLE 01. BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 02. BRONCHODILATORS MARKET FOR ASTHMA MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. BRONCHODILATORS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018–2026 ($MILLION)
TABLE 04. BRONCHODILATORS MARKET FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 05. BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 06. SYMPATHOMIMETICS BRONCHODILATORS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. BRONCHODILATORS FOR ANTICHOLINERGICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. BRONCHODILATORS MARKET FOR PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018–2026 ($MILLION)
TABLE 09. BRONCHODILATORS MARKET FOR COMBINATION DRUGS, BY REGION, 2018–2026 ($MILLION)
TABLE 10. BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 11. BRONCHODILATORS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2018–2026 ($MILLION)
TABLE 12. BRONCHODILATORS MARKET FOR INJECTION, BY REGION, 2018–2026 ($MILLION)
TABLE 13. BRONCHODILATORS MARKET FOR INHALE, BY REGION, 2018–2026 ($MILLION)
TABLE 14. BRONCHODILATORS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 15. NORTH AMERICA BRONCHODILATORS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 16. NORTH AMERICA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 17. NORTH AMERICA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 18. NORTH AMERICA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 19. U.S. BRONCHODILATORS MARKET BY INDICATION, 2018–2026 ($MILLION)
TABLE 20. U.S. BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 21. U.S. BRONCHODILATORS MARKET BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 22. CANADA BRONCHODILATORS MARKET BY INDICATION, 2018–2026 ($MILLION)
TABLE 23. CANADA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 24. CANADA BRONCHODILATORS MARKET BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 25. MEXICO BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 26. MEXICO BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 27. MEXICO BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 28. EUROPE BRONCHODILATORS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 29. EUROPE BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 30. EUROPE BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION),
TABLE 31. EUROPE BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 32. GERMANY BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 33. GERMANY BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 34. GERMANY BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 35. FRANCE BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 36. FRANCE BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 37. FRANCE BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 38. U.K. BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 39. U.K. BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 40. U.K. BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 41. REST OF EUROPE BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 42. REST OF EUROPE BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 43. REST OF EUROPE BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 44. ASIA-PACIFIC BRONCHODILATORS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 45. ASIA-PACIFIC BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 46. ASIA-PACIFIC BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION),
TABLE 47. ASIA-PACIFIC BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 48. JAPAN BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 49. JAPAN BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 50. JAPAN BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 51. CHINA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 52. CHINA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 53. CHINA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 54. INDIA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 55. INDIA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 56. INDIA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 57. REST OF ASIA-PACIFIC BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 58. REST OF ASIA-PACIFIC BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 59. REST OF ASIA-PACIFIC BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 60. LAMEA BRONCHODILATORS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 61. LAMEA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 62. LAMEA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION),
TABLE 63. LAMEA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 64. BRAZIL BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 65. BRAZIL BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 66. BRAZIL BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 67. SAUDI ARABIA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 68. SAUDI ARABIA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 69. SAUDI ARABIA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 70. SOUTH AFRICA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 71. SOUTH AFRICA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 72. SOUTH AFRICA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 73. REST OF LAMEA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 74. REST OF LAMEA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 75. REST OF LAMEA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 76. ABBOTT: COMPANY SNAPSHOT
TABLE 77. ABBOTT: OPERATING BUSINESS SEGMENTS
TABLE 78. ABBOTT PRODUCT PORTFOLIO
TABLE 79. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 80. ASTRAZENECA: OPERATING BUSINESS SEGMENTS
TABLE 81. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 82. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 83. BOEHRINGER INGELHEIM: PRODUCT BUSINESS SEGMENTS
TABLE 84. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 85. GSK.: COMPANY SNAPSHOT
TABLE 86. GSK.: OPERATING BUSINESS SEGMENTS
TABLE 87. GSK.: PRODUCT PORTFOLIO
TABLE 88. ROCHE: COMPANY SNAPSHOT
TABLE 89. ROCHE: OPERATING SEGMENTS
TABLE 90. NOVARTIS: COMPANY SNAPSHOT
TABLE 91. NOVARTIS: OPERATING BUSINESS SEGMENTS
TABLE 92. NOVARTIS: PRODUCT PORTFOLIO
TABLE 93. PFIZER: COMPANY SNAPSHOT
TABLE 94. PFIZER: OPERATING SEGMENTS
TABLE 95. PFIZER: PRODUCT PORTFOLIO
TABLE 96. SANOFI: COMPANY SNAPSHOT
TABLE 97. SANOFI: OPERATING SEGMENTS
TABLE 98. SANOFI: PRODUCT PORTFOLIO
TABLE 99. TEVA: COMPANY SNAPSHOT
TABLE 100. TEVA: PRODUCT PORTFOLIO
TABLE 101. VECTURA: COMPANY SNAPSHOT
TABLE 102. VECTURA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. BRONCHODILATORS, MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP PLAYER POSITIONING
FIGURE 04. DRIVERS, RESTRAINT, AND OPPORTUNITY, BRONCHODILATORS MARKET
FIGURE 05. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET FOR ASTHMA, BY COUNTRY, 2018 & 2026 (%)
FIGURE 06. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 07. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 08. COMPARATIVE SHARE ANALYSIS OF SYMPATHOMIMETICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR ANTICHOLINERGICS BY COUNTRY, 2018 & 2026 (%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR PHOSPHODIESTERASE INHIBITORS BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR COMBINATION DRUGS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR INJECTION, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR INHALER BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. ABBOTT: NET SALES, 2016–2018 ($MILLION)
FIGURE 16. ABBOTT: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 17. ABBOTT: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 18. ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 19. ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 20. BOEHRINGER INGELHEIM: NET SALES, 2016–2018 ($MILLION)
FIGURE 21. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 22. BOEHRINGER INGELHEIM: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 23. GSK: NET SALES, 2016–2018 ($MILLION)
FIGURE 24. GSK: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 25. GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 26. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 27. ROCHE: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 28. ROCHE: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 29. NOVARTIS AG: NET SALES, 2016–2018 ($MILLION)
FIGURE 30. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 31. NOVARTIS AG: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 32. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 33. PFIZER: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 34. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 35. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. SANOFI: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 37. SANOFI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 38. TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 39. TEVA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40. VECTURA: NET SALES, 2016–2018 ($MILLION)
FIGURE 41. VECTURA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 01. BRONCHODILATORS, MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP PLAYER POSITIONING
FIGURE 04. DRIVERS, RESTRAINT, AND OPPORTUNITY, BRONCHODILATORS MARKET
FIGURE 05. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET FOR ASTHMA, BY COUNTRY, 2018 & 2026 (%)
FIGURE 06. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 07. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 08. COMPARATIVE SHARE ANALYSIS OF SYMPATHOMIMETICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR ANTICHOLINERGICS BY COUNTRY, 2018 & 2026 (%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR PHOSPHODIESTERASE INHIBITORS BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR COMBINATION DRUGS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR INJECTION, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR INHALER BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. ABBOTT: NET SALES, 2016–2018 ($MILLION)
FIGURE 16. ABBOTT: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 17. ABBOTT: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 18. ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 19. ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 20. BOEHRINGER INGELHEIM: NET SALES, 2016–2018 ($MILLION)
FIGURE 21. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 22. BOEHRINGER INGELHEIM: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 23. GSK: NET SALES, 2016–2018 ($MILLION)
FIGURE 24. GSK: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 25. GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 26. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 27. ROCHE: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 28. ROCHE: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 29. NOVARTIS AG: NET SALES, 2016–2018 ($MILLION)
FIGURE 30. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 31. NOVARTIS AG: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 32. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 33. PFIZER: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 34. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 35. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. SANOFI: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 37. SANOFI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 38. TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 39. TEVA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40. VECTURA: NET SALES, 2016–2018 ($MILLION)
FIGURE 41. VECTURA: REVENUE SHARE BY REGION, 2018 (%)
